Advertisement
Singapore markets close in 5 hours 41 minutes
  • Straits Times Index

    3,191.88
    +37.19 (+1.18%)
     
  • Nikkei

    38,090.87
    +129.07 (+0.34%)
     
  • Hang Seng

    16,496.66
    +244.82 (+1.51%)
     
  • FTSE 100

    7,847.99
    +27.63 (+0.35%)
     
  • Bitcoin USD

    62,019.74
    -1,978.09 (-3.09%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     
  • Dow

    37,753.31
    -45.66 (-0.12%)
     
  • Nasdaq

    15,683.37
    -181.88 (-1.15%)
     
  • Gold

    2,388.40
    0.00 (0.00%)
     
  • Crude Oil

    82.81
    +0.12 (+0.15%)
     
  • 10-Yr Bond

    4.5850
    -0.0740 (-1.59%)
     
  • FTSE Bursa Malaysia

    1,539.73
    -0.69 (-0.04%)
     
  • Jakarta Composite Index

    7,151.24
    +20.40 (+0.29%)
     
  • PSE Index

    6,542.63
    +92.59 (+1.44%)
     

Teva Pharmaceutical Focusing on Per Product Operating Profits

Teva Pharmaceutical Focusing on Per Product Operating Profits

Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.